Vanda Pharmaceuticals Inc. (VNDA) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Vivian Park

Investors sentiment decreased to 1.29 in 2016 Q4. Its down 1.10, from 2.39 in 2016Q3. It is negative, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 46 reduced holdings. 20 funds opened positions while 55 raised stakes. 39.66 million shares or 1.45% less from 40.25 million shares in 2016Q3 were reported.
Qs Invsts Ltd Liability owns 351,241 shares. Aqr Cap Management Limited Liability Company holds 13,973 shares or 0% of its portfolio. Paloma Mgmt Co accumulated 52,823 shares or 0.01% of the stock. Citadel Advisors Ltd Limited Liability Company stated it has 156,183 shares. Panagora Asset Inc holds 0.01% or 70,230 shares in its portfolio. Palo Alto Ltd Liability Corporation invested in 4.20 million shares or 3.82% of the stock. Gotham Asset Mgmt Limited Liability invested in 60,217 shares or 0.01% of the stock. Wellington Grp Llp holds 165,959 shares. Manufacturers Life Ins The has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Acuta Limited Liability Com invested 0.96% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, Alliancebernstein Lp has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Pacad Limited owns 14,703 shares for 0.03% of their portfolio. Group Incorporated Inc holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 21,072 shares. Product Lc invested 0.11% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). D E Shaw & Communications stated it has 333,619 shares or 0.01% of all its holdings.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 4.25% or $0.75 on September 15, reaching $18.4. About 2.04 million shares traded or 240.41% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since September 17, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 8 months positive chart setup for the $825.39 million company. It was reported on Sep, 17 by Barchart.com. We have $20.06 PT which if reached, will make NASDAQ:VNDA worth $74.29 million more.

Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $-0.10 EPS on November, 1.They anticipate $0.16 EPS change or 266.67 % from last quarter’s $0.06 EPS. After having $-0.03 EPS previously, Vanda Pharmaceuticals Inc.’s analysts see 233.33 % EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 16 analyst reports since September 2, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Thursday, August 3. The rating was reinitiated by Jefferies on Thursday, October 6 with “Buy”. The company was maintained on Monday, June 26 by Jefferies. Jefferies maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday, September 4 with “Buy” rating. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm earned “Buy” rating on Thursday, August 3 by Oppenheimer. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Thursday, August 3. Piper Jaffray has “Buy” rating and $2300 target. The rating was initiated by Aegis Capital on Wednesday, November 9 with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, September 2 report. The firm has “Market Outperform” rating given on Friday, August 26 by JMP Securities.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Zacks.com which released: “Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA …” on August 29, 2017, also Bizjournals.com with their article: “Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer” published on May 04, 2017, Seekingalpha.com published: “Vanda Pharmaceuticals: An Early Stage Bioscience Consideration” on July 26, 2017. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Marketwatch.com and their article: “Vanda Pharma shares decline as goal of itch drug study not reached” published on September 13, 2017 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech …” with publication date: September 06, 2017.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $825.39 million. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ , Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: